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Abstract
Background: Uridine phosphorylase (UPP) is a key enzyme of pyrimidine salvage pathways,
catalyzing the reversible phosphorolysis of ribosides of uracil to nucleobases and ribose 1-
phosphate. It is also a critical enzyme in the activation of pyrimidine-based chemotherapeutic
compounds such a 5-fluorouracil (5-FU) and its prodrug capecitabine. Additionally, an elevated level
of this enzyme in certain tumours is believed to contribute to the selectivity of such drugs.
However, the clinical effectiveness of these fluoropyrimidine antimetabolites is hampered by their
toxicity to normal tissue. In response to this limitation, specific inhibitors of UPP, such as 5-
benzylacyclouridine (BAU), have been developed and investigated for their ability to modulate the
cytotoxic side effects of 5-FU and its derivatives, so as to increase the therapeutic index of these
agents.
Results: In this report we present the high resolution structures of human uridine phosphorylase
1 (hUPP1) in ligand-free and BAU-inhibited conformations. The structures confirm the unexpected
solution observation that the human enzyme is dimeric in contrast to the hexameric assembly
present in microbial UPPs. They also reveal in detail the mechanism by which BAU engages the
active site of the protein and subsequently disables the enzyme by locking the protein in a closed
conformation. The observed inter-domain motion of the dimeric human enzyme is much greater
than that seen in previous UPP structures and may result from the simpler oligomeric organization.
Conclusion: The structural details underlying hUPP1's active site and additional surfaces beyond
these catalytic residues, which coordinate binding of BAU and other acyclouridine analogues,
suggest avenues for future design of more potent inhibitors of this enzyme. Notably, the loop
forming the back wall of the substrate binding pocket is conformationally different and substantially
less flexible in hUPP1 than in previously studied microbial homologues. These distinctions can be
utilized to discover novel inhibitory compounds specifically optimized for efficacy against the human
enzyme as a step toward the development of more effective chemotherapeutic regimens that can
selectively protect normal tissues with inherently lower UPP activity.
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Background
Uridine phosphorylase (UPP; EC 2.4.2.3) is a ubiquitous
enzyme involved in pyrimidine salvage and maintenance
of uridine homeostasis [1-3]. It catalyzes the reversible
phosphorolysis of uracil ribosides and analogous com-
pounds to their respective nucleobases and ribose-1-phos-
phate. The structural mechanisms underlying the catalytic
activity of this enzyme have been extensively studied
through analysis of E. coli UPP (EcUPP) [4-7] and more
recently the S. typhimurium homologue [8]. These struc-
tures have shown UPP to belong to the nucleoside phos-
phorylase (NP) super-family of proteins in the NP-I
subset of proteins possessing α/β folds and trimeric or
hexameric (through trimerization of dimers) quaternary
assemblies [9]. Additionally, based on conservation of
sequence and ligand binding site architecture, it is proba-
ble that the general catalytic mechanism is retained
between UPP and related purine nucleoside phosphory-
lases (PNPs).
Humans possess two isoforms of UPP (hUPP1 [10] &
hUPP2 [11]) of which hUPP1 is more widely distributed,
more abundantly expressed, and better characterized.
hUPP1 has been a subject of interest to cancer researchers
due to its role in the activation of pyrimidine nucleoside
analogues used in chemotherapy, such as 5-fluorouracil
(5-FU) [12] and its prodrug, capecitabine. Further, ele-
vated levels of hUPP1 activity in certain tumours may con-
tribute positively to the selectivity of these cancer-killing
reagents [13]. Other studies have explored the potential of
hUPP1 inhibitors as a means of raising endogenous urid-
ine levels during the course of fluoropyrimidine nucleo-
side treatment, in order to protect normal tissues from the
toxicity of these drugs [14,15]. These inhibitors have been
developed from a family of acyclouridine analogues and
include 5-benzylacyclouridine (BAU) [16], a compound
that has been investigated in clinical trials for its ability to
increase the therapeutic index of 5-FU through induction
of such uridine-mediated rescue [17]. While structures of
EcUPP with BAU and related molecular analogues have
revealed the general mechanistic features of this competi-
tive inhibitor which obstructs the enzyme's active site [7],
the structure of hUPP1 and the details of its specific inter-
actions with this potentially clinically-valuable drug have
not been elucidated.
In the present study, we have determined the crystallo-
graphic structure of hUPP1 at high resolution, both in lig-
and-free and BAU-bound conformations (Table 1). The
structures reveal significant global and local differences
between the human enzyme and its microbial counter-
parts. This knowledge will be valuable in the future dis-
Table 1: Summary of crystallographic data and model refinement
Diffraction Data:
Crystal Form BAU APO
Source SSRL 7-1 SSRL 9-1
λ 1.00 Å 1.00 Å
Space Group P212121 F4132
Cell constants a = 66.20 Å a = 253.78 Å
b = 74.44 Å b = 253.78 Å
c = 262.71 Å c = 253.78 Å
Mosaicity 0.40° 0.41°
Resolution 50-1.90 Å (1.97-1.90 Å) 50-2.3 Å (2.38-2.30 Å)
Rmerge 11.9% (44.1%) 7.2% (38.4%)
I/σ 16.1 (2.0) 30.7 (5.7)
Completeness 99.8% (100.0%) 99.9% (99.7%)
Model Refinement:
Number of reflections 97,957 30,108
Number of monomers/A.U. 4 1
Atoms/A.U. 9466 2396
Protein 9030 2268
Ligand 100 6
Water 336 122
Rcryst 20.5% 20.4%
Rfree 25.1% 22.1%
Rmsd bond lengths 0.018 Å 0.020 Å
Rmsd bond angles 1.72° 1.68°
Ramachandran statistics
Most favored regions 91.5% 91.9%
Additional allowed regions 8.5% 8.1%BMC Structural Biology 2009, 9:14 http://www.biomedcentral.com/1472-6807/9/14
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covery and design of more potent and specific inhibitors
of hUPP1 for development of improved chemotherapeu-
tic regimens.
Results
hUPP1 is a dimeric enzyme
Recombinantly expressed hUPP1 was noted to possess a
smaller than expected quaternary assembly during purifi-
cation by gel filtration. Analysis by both calibrated size-
exclusion chromatography and multi-angle static light
scattering (Figure 1) confirmed that the enzyme was
dimeric in solution, in contrast to the hexameric assembly
predicted from sequence analysis and protein family rela-
tionships [7]. Consistent with this observation, both
solved crystal forms also yielded dimeric enzymes, verify-
ing that the human form of this enzyme has lost the
higher order secondary trimerization of dimers seen in
microbial homologues.
Overall structure of hUPP1
The overall global fold of hUPP1 is highly similar to its
microbial UPP homologues and other members of the
NP-I family of proteins, with two notable exceptions.
First, there is substantial additional architecture at the N-
terminus of the protein forming a strand-turn-strand
structure bracketed by two short helices (Figure 2A). Sec-
ond, the third α-helix of the bacterial enzymes (α3) has
been replaced by an additional strand-turn-strand motif.
While not directly impacting the structure of the active site
of the enzyme, both of these changes increase the buried
surface area of the dimer interface (Figure 2B). Quantita-
tively, these modifications together increase the interface
area between subunits approximately 18%, from 2791 sq.
Å in the E. coli enzyme to 3292 sq. Å in hUPP1.
The alterations occurring around the region of microbial
helix α3 also provide a molecular explanation for the loss
of trimerization of dimers in the human enzyme. The long
loop preceding β* in hUPP1 sterically interferes with the
formation of the protein-protein interface for dimer oli-
gomerization seen in previous structures. Additionally,
the hydrophobic residues ('FPAV') that form the core of
the trimer assembly surface in EcUPP have been mutated
to more polar, solvent-compatible residues in hUPP1
(Figure 2C).
Another difference comparing the hUPP1 structure to pre-
viously studied microbial counterparts is that the stabiliz-
ing K+ binding site observed at the dimer interface of those
proteins [6] is not occupied in either of the determined
human structures (Figure 3). From structure-based
sequence alignment it becomes clear that the primary
coordinating residue (Glu49 in EcUPP) is deleted from
the human proteins with surprisingly little distortion in
the surrounding architecture (Figure 2C). That K+  no
longer plays a role in enzyme stabilization was unex-
pected, as high levels of salt needed to be maintained in
all protein purification and crystallization buffers to pre-
vent hUPP1 aggregation and precipitation.
Binding of the inhibitor BAU to the hUPP1 active site
Analysis of the catalytic active site reveals that BAU binds
hUPP1 in a manner consistent with that previously char-
acterized using EcUPP [7]. In actuality, all residues inter-
acting with the natural uridine and phosphate ligands are
strictly conserved between the two enzymes (Figure 2C).
This fact was unclear prior to this study, as regions of these
proteins between β2 and β3 lack sufficient sequence sim-
ilarity for accurate alignment in the absence of additional
structural data. Despite strict identity retention in ligand-
binding residues, the coordination of the phosphate ion
deviates from that observed in previous microbial struc-
tures (Figure 4A). Specifically, one of the three pocket
arginine residues (Arg64 in hUPP1) is bent away from the
anion, leaving only two coordinating guanidinium
groups, one from each subunit of the dimer, to bind the
substrate. The reason for the unexpected conformation of
this arginine is not immediately apparent, as the back-
bone Cα of this residue is in an equivalent location with
respect to the phosphate molecule as in other structurally
analyzed UPPs. However, in the ligand-free structure of
hUPP1 is a dimeric enzyme Figure 1
hUPP1 is a dimeric enzyme. In contrast to biophysically 
analyzed bacterial forms of uridine phosphorylase, human 
UPP1 is dimeric in solution as analyzed by both calibrated 
size-exclusion chromatography (blue; x-axis) and multi-angle 
light scattering analysis (red; y-axis).BMC Structural Biology 2009, 9:14 http://www.biomedcentral.com/1472-6807/9/14
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Structure of hUPP1 Figure 2
Structure of hUPP1. (A) The global fold of hUPP1 is conserved with its bacterial homologues with only slight modifications. 
The enzyme's N-terminus possesses additional architecture (purple) and the third helix in the E. coli protein (α3) is replaced by 
a sheet-turn-sheet structure (blue). All secondary structure is annotated so as to maintain consistency with prior microbial 
structures. (B) Shown is the dimeric biological unit for hUPP1. It is noteworthy that both of the aforementioned structural 
modifications (purple & blue) result in substantial increases in the buried surface area within the dimer interface of the enzyme. 
(C) Structure-based sequence alignment between the two human enzyme isoforms and structurally analyzed bacterial homo-
logues reveals strict conservation of all of the residues lining the enzyme active site (orange) with the sole exception of a phe-
nylalanine to tyrosine variation at the N-terminus of a residue that contacts primarily inhibitory molecules, such as BAU. There 
are also substantial differences in the loop lining the back of the ligand-binding pocket that similarly interacts only with inhibitor 
chemical groups and not natural substrates (boxed). Modifications underlying loss of dimer trimerization in hUPP1 are high-
lighted in brown. Interestingly, the glutamate implicated in bacterial enzymes in K+ coordination at the dimer interface (yellow) 
is absent from both human proteins. Residues of hUPP1 that are disordered in both structures are hatched.BMC Structural Biology 2009, 9:14 http://www.biomedcentral.com/1472-6807/9/14
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hUPP1 this residue is found to coordinate a sulfate ion
from the crystallization liquor at a position 4.4 Å removed
from the catalytic phosphate binding pocket. This finding
may imply that in the human enzyme this residue has
been adapted to ligand recruitment from the cytoplasm
rather than ligand binding in the active site.
Additional differences between the active sites of human
and bacterial enzymes become apparent when the analy-
sis is extended to regions of these proteins contacting
chemical modifications of acyclouridine analogues such
as BAU. The benzyl ring of this molecule is π-stacked on
one side by Tyr35, a residue that is conserved as phenyla-
lanine in microbes. More significantly, the edge of this
benzyl moiety interacts with a loop region that is struc-
tured very differently in hUPP1 than in EcUPP. In struc-
tures of the E. coli enzyme, the equivalent loop appears
highly flexible, to the point of frequently being too disor-
dered for modelling. These studies concluded that this
loop undergoes an 'induced-fit' conformational change
upon ligand or inhibitor binding (Figure 4B) [6]. In con-
trast, the same loop in hUPP1 is rigid with relatively lower
thermal factors and remains structurally unaltered by BAU
binding. This stability is likely the result of the insertion
within this loop in hUPP1 of two additional residues as
compared to bacterial variants (Figure 2C). These struc-
tural differences have major implications toward under-
standing how various other existing or theoretical
acyclouridine derivatives will interact with the human
enzyme.
Ligand induced motion between hUPP1 domains
Determination of both ligand-free and BAU-bound forms
of hUPP1 allows direct analysis of the conformational
changes induced in the enzyme upon substrate binding.
To this end, there are only subtle differences in the fold
and residue orientation between overlaid monomers of
hUPP1. However, there is a dramatic inter-domain
motion between monomers leading to 3–5 Å changes in
the relative positioning of the loops undergoing the great-
est movement (Figure 5). This hinge-type conformational
change results in a closure of the active site around its sub-
strates and appears to be driven by the formation of inter-
actions between Arg94 and phosphate, His36 and the
ribose sugar group, and Tyr35 and the nucleobase. It is
noteworthy that this domain motion has not been
observed in any of the previously determined microbial
structures despite multiple ligand-free structures, suggest-
ing that the human enzyme is more mobile than its bacte-
rial homologues.
Discussion
Human uridine phosphorylase 1 has been the molecular
target for the design of specific inhibitors intended to
boost endogenous uridine levels for the purpose of rescu-
ing normal tissues from the toxicity of fluoropyrimidine
nucleoside chemotherapeutic agents. The structures
reported here reveal significant differences between
hUPP1 and previously characterized microbial UPPs that
have meaningful implications toward the rational design
of novel reagents with improved potency. In contrast to
Structure of the E. coli K+ binding site in hUPP1 Figure 3
Structure of the E. coli K+ binding site in hUPP1. (A) Structural alignment of the K+ binding site of EcUPP (green) with 
the ligand-free structure of hUPP1 (yellow) reveals both a lack of density for K+ and loss of the coordinating glutamate residues 
(E49). Comparison of the equivalent serine residues (S114 in hUPP1; S73 in EcUPP) shows that rather than binding K+, the 
human residues are turned away from the region and spread further apart by the global inter-domain motion observed for the 
ligand-free enzyme. The electron density for hUPP1 is shown (blue; 2fo-fc map contoured at 2σ) with crystallographic waters 
marked as red crosses. (B) Structural alignment of the K+ binding site of EcUPP (green) with the BAU-bound structure of 
hUPP1 (yellow), shown from the same perspective as in (A), confirms that, despite its inclusion in all crystallization solutions, 
K+ is not present at the dimer interface as previously observed in EcUPP.BMC Structural Biology 2009, 9:14 http://www.biomedcentral.com/1472-6807/9/14
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expectations, hUPP1 is dimeric, having lost the higher
order assembly (trimer-of-dimers) that results in hexam-
eric rings in more primitive UPPs. Possibly as a direct con-
sequence, hUPP1 has two major architectural
modifications, both of which serve to increase the contact
surface area between domains. These alterations likely
increase the stability of dimer association, potentially as
compensation for stability lost on dissolution of the larger
ring complex.
Another implication of the loss of hexameric structure
appears to be that the human enzyme possesses greater
inter-domain flexibility than its microbial counterparts.
While the ability of enzymes to 'breathe' to facilitate sub-
strate and product exchange is a common phenomenon,
it has not been observed in previous studies of UPPs.
Whether this inter-subunit motion has a meaningful
affect on the kinetics and catalytic turnover rates of
hUPP1, in comparison to EcUPP, remains to be investi-
gated. However, the 'open' conformation of hUPP1 pro-
vides the opportunity to potentially develop a novel class
of allosteric inhibitors of this enzyme that lock the protein
in a functionally disabled form, with its catalytic residues
too separated to lyse substrates.
Conclusion
In this report, we present the first structures of human uri-
dine phosphorylase 1. The specific biochemical features
of the human version of this ubiquitous enzyme revealed
by these studies offer improved understanding of how
clinically-evaluated specific inhibitors, such as BAU, bind
to and inactivate this protein. The molecular details
regarding the residues of hUPP1 lining the binding pocket
for such acyclouridine derivatives offer clear approaches
to improving the specificity of these compounds to the
human enzyme. Previous studies have successfully
increased the affinity of acyclouridine analogues to
hUPP1 through the creation of more hydrophobic varia-
tions of BAU such as 5-m-benzyloxybenzylacyclouridine
[16]. Given the recent revelation that BAU may have cross-
reactivity to other human enzymes such as aldehyde oxi-
dase [18], designing rational alterations in the moieties
extending beyond the first benzyl ring may result in sub-
stantial improvements in both compound activity and
selectivity. Extremely high affinity inhibitors of human
PNP (7 pM) have been obtained by using transition state
mimetics derived from immucillins [19]. With the conser-
vation of active site structure and catalytic mechanism
among all NP-I family members, similarly potent antago-
nists of hUPP1 should be creatable. When combined with
strategically selected structure-based modifications to
optimize specificity for this enzyme, there is a strong
potential to develop improved pharmaceuticals for incor-
poration into novel chemotherapeutic regimens with
increased efficacy and reduced toxicity.
BAU binding to hUPP1 Figure 4
BAU binding to hUPP1. (A) BAU and phosphate coordination in hUPP1 is consistent with that previously observed in bac-
terial homologues with the notable exception that R64 (equivalent to R30 in E. coli) does not participate in phosphate binding, 
possessing instead a conformation that distances its guanidinium group from the negatively-charged oxygen atoms of the anion. 
(B) Shown is an alignment of three conformations of the E. coli enzyme with the two hUPP1 structures, focusing on the loop 
toward the back of the active site (human residues 278–284; boxed in Figure 2C). It has been hypothesized that in the bacterial 
enzyme, this loop undergoes an induced-fit conformational change upon ligand binding. In hUPP1, these residues are more 
ordered and conformationally restrained. They do not vary significantly in position between the BAU-bound and ligand-free 
structures, possibly due to the insertion of two additional residues within this region. These differences become increasingly 
important when considering the impacts of chemical modifications to the initial benzyl moiety of BAU, such as the character-
ized UPP inhibitor, 5-m-benzyloxybenzylacyclouridine (BBAU) shown (shaded).BMC Structural Biology 2009, 9:14 http://www.biomedcentral.com/1472-6807/9/14
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Methods
Protein production and purification
Production and isolation of hUPP1 was conducted as pre-
viously reported [20] and followed standard laboratory
protocols for recombinant bacterial protein expression
and purification. In brief, pQE plasmid containing an N-
terminally six histidine-tagged construct of the enzyme
was transformed into BL21(DE3) E. coli. Freshly trans-
formed colonies were cultured in Terrific Broth and
induced with 0.1 mM isopropyl-β-D-thiogalactopyrano-
side (IPTG) at an O.D. of 1.0. Growth was continued over-
night at 18°C. Cells were harvested and resuspended in
50 mM Tris buffer pH 8.0, 300 mM KCl, 10% glycerol
with 20 mM imidazole. The bacteria were then disrupted
by sonication on ice and membranes with other insoluble
material were pelleted by high speed centrifugation
(100,000 × g). Recombinant hUPP1 was subsequently
purified from the resulting supernatant using Ni-NTA
affinity chromatography and batch eluted with 500 mM
imidazole added to the sonication buffer above. Further
purification was conducted using gel filtration chroma-
tography over Superdex 200 resin equilibrated in 300 mM
KCl, 50 mM Tris buffer pH 8.0 with 1 mM Tris (2-carboxy-
ethyl) phosphine (TCEP). The final sample was verified to
be homogenous by SDS-PAGE experiments and used
directly for crystallization or biochemical analysis, as it
was discovered that reduction of the salt concentration of
the buffer below 250 mM at any point during the protein
preparation process led to protein aggregation and precip-
itation.
Crystallization
Large scale preparations of hUPP1 recombinant protein
provided the starting material for initial crystallization tri-
als. Purified hUPP1 at 4 mgs/mL was subject to crystal
screening utilizing the JCSG+ crystallization screen (Qia-
gen) with supplementation of potential ligands BAU, uri-
dine and phosphate. Initial promising leads with BAU
containing 25% PEG 3350 and Bis-Tris buffer pH 5.5 were
optimized to produce large (> 100 microns/dimension)
Ligand mediated inter-domain motion of hUPP1 Figure 5
Ligand mediated inter-domain motion of hUPP1. While the structural conformations of monomers of hUPP1 vary only 
subtly between BAU-bound and ligand-free forms, there is substantial movement between the two domains upon inhibitor 
binding, as illustrated here. In the presence of BAU, phosphate coordination is also promoted within the substrate pocket, 
despite its absence in purification or crystallization solutions. The presence of both molecules within the ligand pocket causes 
the enzyme to dramatically close the active site, resulting in backbone carbon motion of 3–5 Å and individual residue reposi-
tioning of over twice that magnitude. The open state seen for the ligand-free structure of hUPP1 has not been previously 
observed in bacterial homologues, possibly because the hexameric assembly of these microbial enzymes restricts their range of 
inter-domain motion.BMC Structural Biology 2009, 9:14 http://www.biomedcentral.com/1472-6807/9/14
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crystals. Crystals would grow in the same condition in two
morphologies: rods and pyramids; however, the triganol
crystals invariably possessed high mosaicity and low reso-
lution diffraction characteristics. The largest and best dif-
fracting rod crystals were grown in 17% PEG 3350, 100
mM Bis-Tris buffer pH 5.5, 300 mM KCl, 30 mM MgCl2
with 1 mM BAU added to the protein (3 mgs/mL). Crys-
tals were frozen by submersion in liquid nitrogen after a
few seconds incubation in cryoprotectant containing the
above constituents supplemented with 23% ethylene gly-
col. The ligand-free crystal form of hUPP1 was found in
conditions optimized to 1.2 M (NH4)2SO4, 100 mM Bis-
Tris buffer pH 5.5, with 1–2% MPD and protein concen-
tration at 2–3 mgs/mL. Crystals could be grown to very
large diamond-shaped proportions, exceeding 300
microns on each edge. These crystals were frozen by sub-
mersion in liquid nitrogen after a few seconds incubation
in cryoprotectant containing the above constituents sup-
plemented with 25% glycerol.
Data collection/processing and structure determination
Data was collected at SSRL beamlines 7-1 and 9-1 as sum-
marized in Table 1. Complete, high quality datasets to 1.9
Å and 2.3 Å resolution were obtained for the BAU-bound
and ligand-free crystal forms, respectively. Collected data
was processed and reduced by the HKL2000 package with
Denzo and Scalepack [21]. The higher resolution crystal is
of the orthogonal space group P212121 with low mosaic-
ity. The other crystal form belongs to the face-centered
cubic space group F4132. Molecular replacement phasing
of the data obtained on hUPP1 with BAU was successful
using Molrep [22] with dimeric homology models of
hUPP1, based on the BAU-bound E. coli UPP structure
(PDB ID: 1U1C) [7], modified by Swiss-Model [23]. Solu-
tion phases were sufficient to resolve density for the
unmodelled BAU ligand and other unmodelled residues.
The initial model was rebuilt after phases were obtained
using ARP/wARP [24]. Rounds of model building and
refinement were performed using Coot [25] and Refmac
[22]. Due to a lack of electron-density, the first 15 residues
of hUPP1 and the N-terminal cloning artifact residues
'MRGSHHHHHHGSPGLQEF' were not built. Addition-
ally, for the same reason the final two C-terminal residues
could not be modelled in the BAU-bound structure.
Medium non-crystallographic symmetry restraints
(between 4 chains) were retained for the loop residues
79–84 in the BAU-bound structure due to the low quality
of the electron-density map in this region of the protein.
The BAU-bound model includes both a BAU molecule
and a phosphate ion per protein chain as ligands that
could be clearly built into the electron density. The native
hUPP1 structure was completed with a sulfate ion (coor-
dinated by Arg64) and a cation (modelled as magnesium
based on interatomic distances) positioned at a crystal
contact point between the side chain oxygen atoms of
Asp212 and Ser116 of a symmetry-related chain. The final
structures were refined with Refmac to an Rfactor/Rfree of
20.5%/25.1% respectively for the BAU-bound structure,
and 20.4%/22.1% for the ligand-free structure of the
enzyme, with approximately 92% of residues in most
favorable regions of the Ramachandran plot as analyzed
by Procheck [26]. The models were further validated using
Molprobity [27], scoring in the 91st and 97th percentile,
respectively. Figures were rendered using ICM Browser-
Pro (Molsoft). The atomic coordinates and structure fac-
tors have been deposited in the Protein Data Bank (3EUF
and 3EUE).
Multi-angle light scattering analysis
Recombinant hUPP1 was analyzed using size exclusion
chromatography over a calibrated Superdex 200 column
on an Äcta Basic FPLC (GE) with an in-line MiniDAWN
TREOS light scattering detector (Wyatt Technology) for in
solution characterization of absolute molecular weight,
size, and quaternary assembly, in combination with an
Optilab rEX refractive index detector, in accordance with
the Wyatt manual. The running buffer was comprised of
300 mM KCl, 50 mM Tris buffer pH 8.0, and 1 mM TCEP.
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